291 research outputs found
NephroCheck data compared to serum creatinine in various clinical settings
Figure B: TIMP-2 immunofluorescence staining of tubular cells in the urine sediment of patient #2. (TIF 6713 kb
MK2 and ETV1 Are Prognostic Factors in Esophageal Adenocarcinomas
Background. Esophageal cancer is ranked in the top ten of diagnosed tumors worldwide. Even though
improvements in survival could be noticed over the last years, prognosis remains poor. ETS
translocation variant 1 (ETV1) is a member of a family of transcription factors and is phosphorylated
by mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MK2). Aim of this study was
to evaluate the prognostic role of MK2 and ETV1 in esophageal cancer.
Methods. Consecutive patients that underwent surgical resection at the department of surgery at the
Medical University of Vienna between 1991 and 2012 were included into this study. After
microscopic analysis, tissue micro arrays (TMAs) were created and immunohistochemistry was
performed with antibodies against MK2 and ETV1.
Results. 323 patients were included in this study. Clinical data was achieved from a prospective
patient data base. Nuclear overexpression of MK2 was observed in 143 (44.3%) cases for nuclear
staining and in 142 (44.0%) cases a cytoplasmic overexpression of MK2 was observed. Nuclear and
cytoplasmic ETV1 overexpression was detected in 20 cases (6.2%) and 30 cases (9.3%), respectively.
In univariate survival analysis, cMK2 and nETV1 were found to be significantly associated with
patients' overall survival. Whereas overexpression of cMK2 was associated with shorter, nETV1
was associated with longer overall survival. In multivariate survival analysis, both cMK2 and nETV1
were found to be independent prognostic factors for the subgroup of EAC as well.
Discussion. Expression of MK2 and ETV1 are prognostic factors in patients, with esophageal
adenocarcinoma
Exploring possible links between Quaternary aggradation in the Upper Rhine Graben and the glaciation history of northern Switzerland
The Quaternary filling of the Upper Rhine Graben is an excellent archive to reconstruct sediment dynamics in response to climate change, in particular related to past glaciations of the Swiss Alpine Foreland. Here, a sediment sequence recovered by drilling for exploration purposes near Kronau is investigated, using a combination of sedimentological logging, provenance studies (heavy minerals and clast petrography), and luminescence dating. Several phases of coarse sediment aggradation are identified that possibly correlate to Marine Isotope Stages (MIS) 12 (478-424 ka), 10 (374-337 ka), 8 (300-243 ka), 6 (191-130 ka) and/or 4 (71-57 ka), and 2 (29-14 ka). Several of these phases have previously also been reported from cores recovered in the major Quaternary depo-centre near Heidelberg. This suggests that the observed coarse aggradation in the Upper Rhine Graben can be assigned to various glaciations in northern Switzerland: Mohlin (MIS 12), Habsburg (MIS 10 or 8), Beringen (MIS 6), an unnamed glacial advance during MIS 4, and Birrfeld (MIS 2). However, due to the limited data available, this hypothesis and the suggested correlations require further confirmation by applying the approach presented here to further cores from the Upper Rhine Graben.</p
How we treat patients with leptomeningeal metastases
The goal of treatment of leptomeningeal metastasis is
to improve survival and to maintain quality of life by
delaying neurological deterioration. Tumour-specific
therapeutic options in
Radiomics in neuro-oncological clinical trials
The development of clinical trials has led to substantial improvements in the prevention and treatment of many diseases, including brain cancer. Advances in medicine, such as improved surgical techniques, the development of new drugs and devices, the use of statistical methods in research, and the development of codes of ethics, have considerably influenced the way clinical trials are conducted today. In addition, methods from the broad field of artificial intelligence, such as radiomics, have the potential to considerably affect clinical trials and clinical practice in the future. Radiomics is a method to extract undiscovered features from routinely acquired imaging data that can neither be captured by means of human perception nor conventional image analysis. In patients with brain cancer, radiomics has shown its potential for the non-invasive identification of prognostic biomarkers, automated response assessment, and differentiation between treatment-related changes from tumour progression. Despite promising results, radiomics is not yet established in routine clinical practice nor in clinical trials. In this Viewpoint, the European Organization for Research and Treatment of Cancer Brain Tumour Group summarises the current status of radiomics, discusses its potential and limitations, envisions its future role in clinical trials in neuro-oncology, and provides guidance on how to address the challenges in radiomics
Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion
This article is the result of a round table discussion held at the European Lung Cancer Conference (ELCC) in Geneva in May 2017. Its purpose is to explore and discuss the advances in the knowledge about the biology and treatment of brain metastases originating from non-small cell lung cancer. The authors propose a series of recommendations for research and treatment within the discussed context
Growth differentiation factor-15 and prediction of cancer-associated thrombosis and mortality: a prospective cohort study
Background
Patients with cancer are at increased risk of venous thromboembolism (VTE) and arterial thromboembolic/thrombotic events (ATEs). Growth differentiation factor-15 (GDF-15) improves cardiovascular risk assessment, but its predictive utility in patients with cancer remains undefined.
Objectives
To investigate the association of GDF-15 with the risks of VTE, ATE, and mortality in patients with cancer and its predictive utility alongside established models.
Methods
The Vienna Cancer and Thrombosis Study (CATS)âa prospective, observational cohort study of patients with newly diagnosed or recurrent cancerâwhich was followed for 2 years, served as the study framework. Serum GDF-15 levels at study inclusion were measured, and any association with VTE, ATE, and death was determined using competing risk (VTE/ATE) or Cox regression (death) modeling. The added value of GDF-15 to established VTE risk prediction models was assessed using the Khorana and Vienna CATScore.
Results
Among 1531 included patients with cancer (median age, 62 years; 53% men), median GDF-15 levels were 1004 ng/L (IQR, 654-1750). Increasing levels of GDF-15 were associated with the increased risks of VTE, ATE, and all-cause death ([subdistribution] hazard ratio per doubling, 1.16 [95% CI, 1.03-1.32], 1.30 [95% CI, 1.11-1.53], and 1.57 [95% CI, 1.46-1.69], respectively). After adjustment for clinically relevant covariates, the association only prevailed for all-cause death (hazard ratio, 1.21; 95% CI, 1.10-1.33) and GDF-15 did not improve the performance of the Khorana or Vienna CATScore.
Conclusion
GDF-15 is strongly associated with survival in patients with cancer, independent of the established risk factors. While an association with ATE and VTE was identified in univariable analysis, GDF-15 was not independently associated with these outcomes and failed to improve established VTE prediction models
Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial
BACKGROUND: Temporal muscle thickness (TMT) was described as surrogate marker of skeletal muscle mass. This study aimed to evaluate the prognostic relevance of TMT in patients with progressive glioblastoma.
METHODS: TMT was analyzed on cranial magnetic resonance images of 596 patients with progression of glioblastoma after radio-chemotherapy enrolled in the EORTC 26101 trial. An optimal TMT cutoff for overall survival (OS) and progression free survival (PFS) was defined in the training cohort (n=260, phase 2). Patients were grouped as "below" or "above" the TMT cutoff and associations with OS and PFS were tested using the Cox model adjusted for important risk factors. Findings were validated in a test cohort (n=308, phase 3).
RESULTS: An optimal baseline TMT cutoff of 7.2 mm was obtained in the training cohort for both OS and PFS (AUC=0.64). Univariate analyses estimated a hazard ratio (HR) of 0.54 (95% CI: 0.42, 0.70, p<0.0001) for OS and a HR of 0.49 (95% CI: 0.38, 0.64, p<0.0001) for PFS for the comparison of training cohort patients above versus below the TMT cutoff. Similar results were obtained in Cox models adjusted for important risk factors with relevance in the trial for OS (HR of 0.54, 95% CI: 0.41, 0.70, p<0.0001) and PFS (HR of 0.47, 95% CI: 0.36, 0.61, p<0.0001). Results were confirmed in the validation cohort.
CONCLUSION: Reduced TMT is an independent negative prognostic parameter in patients with progressive glioblastoma and may help to facilitate patient management by supporting patient stratification for therapeutic interventions or clinical trials
Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma
Background
Levetiracetam (LEV) is one of the most frequently used antiepileptic drugs (AED) for brain tumor patients with seizures. We hypothesized that toxicity of LEV and temozolomide-based chemoradiotherapy may overlap.
Methods
Using a pooled cohort of patients with newly diagnosed glioblastoma included in clinical trials prior to chemoradiotherapy (CENTRIC, CORE, AVAglio) or prior to maintenance therapy (ACT-IV), we tested associations of hematologic toxicity, nausea or emesis, fatigue, and psychiatric adverse events during concomitant and maintenance treatment with the use of LEV alone or with other AED versus other AED alone or in combination versus no AED use at the start of chemoradiotherapy and of maintenance treatment.
Results
Of 1681 and 2020 patients who started concomitant chemoradiotherapy and maintenance temozolomide, respectively, 473 and 714 patients (28.1% and 35.3%) were treated with a LEV-containing regimen, 538 and 475 patients (32.0% and 23.5%) with other AED, and 670 and 831 patients (39.9% and 41.1%) had no AED. LEV was associated with higher risk of psychiatric adverse events during concomitant treatment in univariable and multivariable analyses (RR 1.86 and 1.88, Pâ
<â
.001) while there were no associations with hematologic toxicity, nausea or emesis, or fatigue. LEV was associated with reduced risk of nausea or emesis during maintenance treatment in multivariable analysis (HRâ
=â
0.80, Pâ
=â
.017) while there were no associations with hematologic toxicity, fatigue, or psychiatric adverse events.
Conclusions
LEV is not associated with reduced tolerability of chemoradiotherapy in patients with glioblastoma regarding hematologic toxicity and fatigue. Antiemetic properties of LEV may be beneficial during maintenance temozolomide
Recommended from our members
Sarcopenia in Neurological Patients: Standard Values for Temporal Muscle Thickness and Muscle Strength Evaluation.
Temporal muscle thickness (TMT) was investigated as a novel surrogate marker on MRI examinations of the brain, to detect patients who may be at risk for sarcopenia. TMT was analyzed in a retrospective, normal collective cohort (n = 624), to establish standard reference values. These reference values were correlated with grip strength measurements and body mass index (BMI) in 422 healthy volunteers and validated in a prospective cohort (n = 130) of patients with various neurological disorders. Pearson correlation revealed a strong association between TMT and grip strength (retrospective cohort, Ï = 0.746; p < 0.001; prospective cohort, Ï = 0.649; p < 0.001). A low or no association was found between TMT and age (retrospective cohort, R2 correlation coefficient 0.20; p < 0.001; prospective cohort, Ï = -0.199; p = 0.023), or BMI (retrospective cohort, Ï = 0.116; p = 0.042; prospective cohort, Ï = 0.227; p = 0.009), respectively. Male patients with temporal wasting and unintended weight loss, respectively, showed significantly lower TMT values (p = 0.04 and p = 0.015, unpaired t-test). TMT showed a high correlation with muscle strength in healthy individuals and in patients with various neurological disorders. Therefore, TMT should be integrated into the diagnostic workup of neurological patients, to prevent, delay, or treat sarcopenia
- âŠ